A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B

被引:18
作者
Lantto, J
Fletcher, JM
Ohlin, M
机构
[1] Lund Univ, Dept Immunotechnol, S-22007 Lund, Sweden
[2] Royal Free & UCL, Sch Med, Dept Immunol, London NW3 2PF, England
关键词
D O I
10.1099/0022-1317-83-8-2001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Glycoprotein B (913) of human cytomegalovirus (HCMV) is the dominating protein in the envelope of this virus and gives rise to virus-neutralizing antibodies in most infected individuals. We have previously isolated a neutralizing human antibody specific for antigenic domain 2 (AD-2) on gB, a poorly immunogenic epitope, which nevertheless is capable of eliciting potent neutralizing antibodies. In order to define parameters important for the neutralization of HCMV via gB, we have investigated the virus-neutralizing capacity and the kinetics of the interaction with AD-2 of the monomeric and dimeric forms of a single chain variable fragment (scFv) corresponding to this antibody. We demonstrate here that neutralization of HCMV via AD-2 on gB can be mediated by dimeric scFv, while monomeric fragments cannot mediate neutralization of the virus, despite a slow dissociation from the intact glycoprotein. This finding is discussed in the context of possible mechanisms for antibody-mediated virus neutralization.
引用
收藏
页码:2001 / 2005
页数:5
相关论文
共 27 条
[1]   DIFFERENT ANTIBODY-RESPONSE TO A NEUTRALIZING EPITOPE OF HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN-B AMONG SEROPOSITIVE INDIVIDUALS [J].
AYATA, M ;
SUGANO, T ;
MURAYAMA, T ;
SAKAMURO, D ;
TAKEGAMI, T ;
MATSUMOTO, Y ;
FURUKAWA, T .
JOURNAL OF MEDICAL VIROLOGY, 1994, 43 (04) :386-392
[2]   PHASE-I STUDY ON HUMAN MONOCLONAL-ANTIBODY AGAINST CYTOMEGALOVIRUS - PHARMACOKINETICS AND IMMUNOGENICITY [J].
AZUMA, J ;
KURIMOTO, T ;
TSUJI, S ;
MOCHIZUKI, N ;
FUJINAGA, S ;
MATSUMOTO, Y ;
MASUHO, Y .
JOURNAL OF IMMUNOTHERAPY, 1991, 10 (04) :278-285
[3]   OLIGOMERIZATION OF THE HUMAN CYTOMEGALOVIRUS MAJOR ENVELOPE GLYCOPROTEIN COMPLEX GB (GP55-116) [J].
BRITT, WJ ;
VUGLER, LG .
JOURNAL OF VIROLOGY, 1992, 66 (11) :6747-6754
[4]   CELL-SURFACE EXPRESSION OF HUMAN CYTOMEGALOVIRUS (HCMV) GP55-116 (GB) - USE OF HCMV-RECOMBINANT VACCINIA VIRUS-INFECTED CELLS IN ANALYSIS OF THE HUMAN NEUTRALIZING ANTIBODY-RESPONSE [J].
BRITT, WJ ;
VUGLER, L ;
BUTFILOSKI, EJ ;
STEPHENS, EB .
JOURNAL OF VIROLOGY, 1990, 64 (03) :1079-1085
[5]   Antibody and virus: Binding and neutralization [J].
Burton, DR ;
Williamson, RA ;
Parren, PWHI .
VIROLOGY, 2000, 270 (01) :1-3
[6]  
Burton DR, 2001, CURR TOP MICROBIOL, V260, P109
[7]   Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not [J].
Drew, PD ;
Moss, MT ;
Pasieka, TJ ;
Grose, C ;
Harris, WJ ;
Porter, AJR .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :1959-1963
[8]   THE OUTCOME OF CONGENITAL CYTOMEGALOVIRUS-INFECTION IN RELATION TO MATERNAL ANTIBODY STATUS [J].
FOWLER, KB ;
STAGNO, S ;
PASS, RF ;
BRITT, WJ ;
BOLL, TJ ;
ALFORD, CA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (10) :663-667
[9]  
HO M, 1991, CYTOMEGALOVIRUS BIOL, P440
[10]   A SHORT POLYPEPTIDE MARKER SEQUENCE USEFUL FOR RECOMBINANT PROTEIN IDENTIFICATION AND PURIFICATION [J].
HOPP, TP ;
PRICKETT, KS ;
PRICE, VL ;
LIBBY, RT ;
MARCH, CJ ;
CERRETTI, DP ;
URDAL, DL ;
CONLON, PJ .
BIO-TECHNOLOGY, 1988, 6 (10) :1204-1210